| Date | Title | Description |
| 18.05.2020 | Seraphina Therapeutics Reveals Groundbreaking Fatty Acid Discovery, Secures $5.5M in Series A Round | Seraphina Therapeutics, Inc., announced today its Series A fundraise of $5.5 million, led by Domain Associates, and reveals it is the first to discover pentadecanoic acid, the first potential essential fatty acid to be discovered in 90 year... |
| 20.11.2019 | With echoes of Theranos, Truvian Sciences revives the dream of low-cost, accessible blood tests | A little over a year after the dissolution of the once high-flying blood testing startup Theranos, another startup has raised more than $27 million to breathe new life into the vision of bringing low-cost blood tests to point-of-care medica... |
| 01.08.2017 | Tekla Capital Joins $55M Series C for Milestone Pharmaceuticals | Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing. The round was led by Novo Holdings A/S, and included new investors Forbion Capi... |
| 01.08.2017 | Domain Associates Joins $55M Series C for Milestone Pharmaceuticals | Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today announced the completion of a US$55 million Series C financing. The round was led by Novo Holdings A/S, and included new investors Forbion Capi... |
| 25.07.2017 | Domain Associates Leads $20M Series D for Sebacia | Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates... |
| 21.05.2017 | Iterum Raises $65M Series B | Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo... |
| 21.05.2017 | Domain Associates Joins $65M Series B for Iterum | Iterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, today announced that it has clo... |
| 30.04.2017 | Domain Associates Joins $40M Series D for Epic Sciences | Epic Sciences (Epic) announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabb... |
| 27.04.2017 | NEA Leads $12M Series B for ChromaCode | ChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Series B funding. This latest round is led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates, who ... |
| 27.04.2017 | Domain Associates Joins $12M Series B for ChromaCode | ChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Series B funding. This latest round is led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates, who ... |
| 09.12.2016 | Term Sheet — Friday, December 9 | Layoff Watch and Founder-Friendly Boards
It’s the kind of thing that stinks to be right about. Earlier this week I predicted that many startups would go through end-of-year layoffs. Some are trimming headcount after over-expanding relative ... |
| 09.12.2016 | Domain Associates Closes Latest Life Sciences Venture Capital Fund, at $163.6M | Domain Associates, a San Diego, CA and Princeton, NJ-based venture capital firm focused on the life sciences sector, closed its latest fund at $163.6m.
According to a regulatory form filed with the SEC, Domain Partners IX, L.P. was subscrib... |
| 19.11.2015 | Daily funding roundup - November 19, 2015 | PresenceLearning raised $25M; UrbanClap scored $25M; Cinematique closed $3.5M funding
Touchable video platform Cinematique, announced on Thursday that it has closed $3.5 million in a funding round led by Pumori Capital, an investment adviso... |
| 24.10.2015 | A look at the underbelly of Theranos, plus 5 must-read stories from MedCity News this week | 1. Genetic testing turns quick ROI in Aetna wellness program
Aetna is crediting genetic testing of employees for risk of metabolic syndrome for producing a quick return on investment in an employee wellness program.
The health insurer saved... |
| 20.10.2015 | Watch out, Theranos? Edico Genome CEO backing stealth one-drop-of-blood startup | Given the recent focus on single drop of blood diagnostics, it’s safe to assume this Dx company is focusing on this hot segment of the industry. And it’s probably prudent to stay stealth at this point – Theranos is in a world of hurt follow... |
| 10.07.2015 | Xagenic Raises CAD$15M in Funding | Xagenic, a Toronto, Canada-based molecular diagnostics company developing the lab-free Xagenic X1™ platform for use at the point of care, raised CAD$15M in funding.
Backers included Domain Associates, CTI Life Sciences, BDC Capital and the ... |
| 17.09.2014 | RightCare Solutions secures $4 million investment from NewSpring Capital | In addition to Murphy, other members include Dennis Podlesak and Jesse Treu from venture firm Domain Associates and Richard Perlman of Compass Partners, as well as Dr. Peter Bach, a physician from Memorial Sloan Kettering Cancer Center.
[Ph... |
| 04.09.2014 | Fractyl Laboratories Secures $40M in Series C Funding | Fractyl Laboratories, a Waltham, Mass.-based developer of a device-based endoscopic procedure to treat Type 2 diabetes, secured $40m in Series C funding.
The round was led by Mithril with participation from General Catalyst, Bessemer Ventur... |
| 18.06.2014 | Benvenue Medical secures $40M Series E to beef up manufacturing, U.S. commercialization | InterWest Partners led the round, and general partner Dr. Gil Kliman was appointed to Benvenue’s board. Other investors include DeNovo Ventures, Domain Associates, Technology Partners and Versant Ventures. Silicon Valley Bank was the sole d... |
| 11.12.2013 | Domain VC: Why we’re investing more in molecular diagnostics | Some firms have pulled back on investing in molecular diagnostics, and Silicon Valley Bank life science described in an M&A report last year how the sector didn’t see as many big exits as expected between 2009 and 2011 (PDF).
Kamdar sai... |
| 02.12.2013 | Xagenic Closes $20M Series B Financing | Xagenic Inc., a Toronto, Canada-based molecular diagnostics company, closed a $20m Series B financing.
The round was led by new investor Domain Associates, LLC, with participation from existing investors CTI Life Sciences Fund and the Ontar... |
| 13.11.2013 | Health IT company nets $5M for tool to lower readmissions | Last year, Right Care netted $1.76 million in a series A round. It has done several implementations with academic health systems demonstrating meaningful clinical improvements and return on investment. It’s part of University of Pennsylvani... |
| 04.11.2013 | Healthcare startup with noninvasive, one-time wet AMD treatment touts two years of success | Anti-VEGF therapy proved to be a major breakthrough in treatment for wet AMD. The drugs could halt the progression of the disease and even recapture some lost vision, Taylor said. But the drugs are a chronic therapy. “The patient should go ... |
| 04.10.2013 | $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | The vaccine contains a recombinant form of Als3, a protein found on the surface of Candida albicans which helps it bind to and invade human endothelial cells. The synthetic version of the protein used in the vaccine is produced by the ferme... |
| 03.10.2013 | NovaDigm Therapeutics Closes $14M Series B Financing | NovaDigm Therapeutics, a Grand Forks, North Dakota-based developer of vaccines for fungal and bacterial infections, closed a $14m Series B financing.
Backers included new investor RusnanoMedInvest and current investor Domain Associates.
Led... |
| 29.07.2013 | Domain's $760 million co-investment partnership with Rusnano bears fruit with fifth transaction funded Manufacturing facility in Russia to break ground this year, seeks to license rights from addition... | |
| 29.07.2013 |
Domain Associates: Fifth Investment With Rusnano From $760M Fund
| San Diego-based venture investor Domain Associates is reporting today that a fifth company in its portfolio--ReVision Optics--has received funding via its agreement with Rusnano, the Russian state's investment corporation. Revision optics a... |
| 12.06.2013 |
Domain Associates Promotes Shah To Partner
| San Diego-based biotech investment firm Domain Associates announced this morning that it has promoted Nimesh Shah to Partner at the firm. Shah has been at the firm since 2006. Shah sits on the boards of Zyga Technology, Benvenue Medical, Co... |
| 25.04.2013 | Esperion Therapeutics Raises $33M to Further Clinical Trials | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The Ann Arbor-based biotech company Esperion Therapeutics announced today that it has completed a $33 million round of preferred stock financing. Longitude Capital led the rou... |
| 25.04.2013 | Esperion Therapeutics Completes $33M Financing | Esperion Therapeutics, Inc., a Plymouth, MI-based clinical stage biopharmaceutical company, completed a $33m financing.
The round was led by new investor Longitude Capital, with participation from existing investors Aisling Capital, Alta Pa... |
| 16.04.2013 | Why digital health is no ‘bubble’ | Paul Sonnier is Head of Digital Health Strategy at specialty life sciences consulting firm Popper and Company.
There’s been discussion recently about a lack of life science venture capital enthusiasm for emerging digital health companies. I... |
| 19.12.2012 |
Domain Associates, Rusnano Boost Three Firms By $93M
| San Diego-based venture capital firm Domain Associates and its Russian partner, Rusnano, have put part of their $760M, late stage investment fund to work, investing a total of $93M in funding in three portfolio companies of Domain. The two ... |
| 19.12.2012 | Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty | Other treatment programs in its pipeline that will benefit from the new funding include its REG1 indication for transaortic valve implantation and its treatment for diabetic vasculopathy, a blood vessel disorder, expected to begin Phase 1 c... |
| 13.11.2012 | Cancer diagnostics firm that can enable personalized medicine raises $13M in series B financing | “Epic’s technology has achieved an unprecedented level of sensitivity in detecting circulating tumor cells to develop crucial cancer diagnostics for the millions of patients who need to understand whether their treatment is working and the ... |
| 13.11.2012 | Epic Sciences Completes $13M Series B Equity Financing | Epic Sciences, Inc., a San Diego, CA-based biotech company that develops cancer diagnostics, has completed a $13m Series B equity financing.
Backers include new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments... |
| 11.10.2012 | Discharge decision support startup feted by Janssen raises $1.75M in series A | The Fort Washington, Pennsylvania company was co-founded by CEO Eric Heil and Kathy Bowles, a professor with the University of Pennsylvania School of Nursing. Bowles received $5 million in funding from the National Institutes of Health to h... |
| 03.10.2012 | Biotech company developing therapies for macular edema raises $40 million | Solution/Product: The company makes the Iluvien drug delivery system that is implanted at the back of the eye and is designed to release sub-microgram levels of fluocinolone acetonide for up to 36 months to treat chronic diabetic macular ed... |
| 24.05.2012 | Cash from innovation challenges will provide pilot testing for readmission, diabetes education software | A readmission risk assessment tool and two diabetes education programs will now be put to the ultimate reality check: patients.
The winner of the Janssen Connected Care Challenge and finalists in Sanofi’s Data Design Diabetes Innovation Cha... |
| 14.05.2012 | Health IT tool to reduce hospital readmissions identifies vulnerable patients earlier | A healthcare IT program aimed at reducing hospital readmissions by more effectively coordinating vulnerable patients’ hospital discharge and follow-up care has been utilized by four hospital pilot partners.
RightCare Solutions, developed by... |
| 08.03.2012 | Morning Read: Personal genetic map may soon be as cheap as a big screen TV | Doctors say that investing time to create videos and blog posts makes for more productive use of face-to-face time with patients. Inspired by the model of the Khan Academy, physicians are using social media platforms to cover frequently ask... |
| 18.01.2012 | Carticept Medical Closes $10M Financing | Carticept Medical, Inc., an Alpharetta, Ga.-based developer of innovative products for the treatment of cartilage injuries and osteoarthritis, has completed a $10m financing round.
The round was led by existing investors Domain Associates, ... |
| 09.01.2012 | Aria Diagnostics Raises Over $50m in Series C Funding | Aria Diagnostics (formerly known as Tandem Diagnostics), a San Jose, Calif.-based molecular diagnostics company, has secured more than $50m in Series C funding.
New investors Meritech Capital Partners and a prominent mutual fund group have ... |
| 30.12.2011 | Celator Pharmaceuticals raising $5 million for cancer treatments | The Celator’s approach to cancer treatment is based on a synergistic ratio of drugs to improve tumor cell kill and locks the synergistic ratio in a drug-delivery vehicle to maintain the ratio in patients, according to its website. The goal ... |
| 15.11.2011 | Sera Prognostics Raises $19.3M in Series A Funding | Sera Prognostics Inc., a Salt Lake City, UT–based company that develops tests to diagnose preterm birth and other pregnancy complications, has raised $19.3m in Series A funding.
The round was led by venture capital firms InterWest Partners,... |
| 22.02.2011 | Early stage biotechs face funding gap as VCs seek surer bets, stronger returns | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recov... |
| 03.06.2010 | Apnex taps Boston Scientific vet as CEO | By Thomas Lee
Apnex Medical Inc., a St. Paul, Minn.-based start-up developing technology to treat obstructive sleep apnea, named Charles McKhann as its new CEO.
McKhann, who previously served as a global vice president of marketing for Bost... |
| 02.06.2010 | Apnex Medical names former BSX and J&J executive as its new CEO | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 10.08.2009 | Domain Associates closes $500 million life science fund | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 20.07.2009 | Oraya scores $42M for eye radiation treatments | Oraya Therapeutics, maker of radiosurgical tools used to treat eye diseases, has brought in $42 million in a third round of funding from Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.
B... |
| 16.06.2009 | SkinMedica scratches up $9.4M for anti-aging pharmaceuticals | SkinMedica, maker of specialized anti-aging treatments, has raised $9.4 million in equity and rights. It adds this amount to the $103.4 million in venture capital it previously brought in from a bevy of investors including Aisling Capital, ... |
| 15.04.2009 | Cancer drug maker BiPar sells to Sanofi-aventis for $500M | BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divid... |
| 13.04.2009 | Philanthropic fund of funds Legacy closes $276M | Legacy Venture, the Palo Alto, Calif. firm that holds a portfolio of other investment funds and distributes returns to charities, announced that it closed a new $276 million fund, its fifth, despite adverse economic conditions. Basically, L... |
| 10.04.2009 | Cell Biosciences to launch new tech with $10M | Cell Biosciences announced that it’s just brought in $10 million in a third round of funding to launch its new protein analysis technology used to track cellular pathways. It plans to sell its products to labs and research institutions that... |
| 09.04.2009 | Investors give up on diabetes drug maker DiObex | After failing to raise a sustaining round of capital, DiObex has been effectively shut down by its investors. They have laid off the San Francisco company’s eight employees and are moving to quickly sell off its assets, including its lead d... |
| 18.02.2009 | Public biotech firms Cadence, Affymax draw $128M from bargain-hunting VCs | Much has been written about how the IPO market froze out biotech companies in 2008, but it looks like times are also tough for those who went public before the economy soured. Cadence Pharmaceuticals has seen a dip in stock price from $9 to... |
| 14.01.2009 | Corthera adds $10M for heart failure medication | Pharmaceutical company Corthera just took $10 million to close a $23 million third round of funding but is already looking to raise $40 to $50 million in a new fourth round by March to support clinical trials of a drug that could ease sympt... |
| 13.01.2009 | BiPar snags $20M for inhibitor-based cancer therapies | Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based co... |
| 09.01.2009 | Achaogen takes in $5.6M to fight bacterial infections | Pharmaceutical company Achaogen received a $5.6 million grant from the U.K.-based Wellcome Trust as part of its Seeding Drug Discovery Initiative. The money will go toward phase one clinical trials of the San Francisco company’s lead drug c... |
| 29.10.2008 | BioLogix bags $6M for oncology drug, names new CEO | Biopharm company BioLogix raised $6 million in first-round equity and debt financing from Essex Woodlands Health Ventures and New Science Ventures. The money will be used to continue development of its top cancer-fighting compound, but a se... |
| 15.05.2007 | Apnex Medical raises $16.1M for sleep-apnea devices | Apnex Medical, a Minneapolis maker of implants for the treatment of obstructive sleep apnea, raised $16.1 million in a first round of funding. Participants included Domain Associates, New Enterprise Associates, Polaris Ventures Partners and... |
| - | Health IT tool to reduce hospital readmissions identifies vulnerable patients earlier | A healthcare IT program aimed at reducing hospital readmissions by more effectively coordinating vulnerable patients’ hospital discharge and follow-up care has been utilized by four hospital pilot partners.
RightCare Solutions, developed by... |
| - | Domain Associates closes $500 million life science fund | PRINCETON, New Jersey — Venture fund Domain Associates has closed a $500 million fund to invest in early-stage drug and medical device companies with “meaningful portion of its efforts going towards the diagnostics and instrumentation secto... |
| - | $14M round for ‘cross-kingdom vaccine’ maker will fund trials in prevention of yeast infections | Whereas most vaccines under development are designed to protect against one kind of pathogen, NovaDigm Therapeutics thinks a vaccine it’s developing could protect against certain fungal and bacterial infections caused by several species of ... |
| - | Celator Pharmaceuticals raising $5 million for cancer treatments | Celator Pharmaceuticals, a drug development company, is raising $5 million as its drug therapy for acute myeloid leukemia moves through phase 2 clinical trials.
In its latest financing round, the company, which has offices in Princeton, New... |
| - | Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty | In one of the largest financing rounds this year, biopharmaceutical startup Regado Biosciences has raised $51 million to advance its anti-clotting therapeutic through Phase 3 clinical trials.
A subsidiary of Russian investment firm Rusnano,... |
| - | RightCare Solutions secures $4 million investment from NewSpring Capital | A Philadelphia health IT company that developed a predictive analytics tool to help hospitals get a handle on care coordination to reduce readmissions has raised $4 million to support its national expansion. NewSpring Capital provided the f... |
| - | Cancer diagnostics firm that can enable personalized medicine raises $13M in series B financing | San Diego-based biotech firm Epic Sciences announced Tuesday that the company has raised $13 million to pursue its molecular diagnostics technology that can better detect and monitor cancer as well as enable personalize cancer treatment.
In... |
| - | Healthcare startup with noninvasive, one-time wet AMD treatment touts two years of success | Oraya Therapeutics, one of California’s many healthcare startups, has distinguished itself from the crowd. The medical device company recently presented results from a two-year study showing its IRay, a low-voltage, stereotactic, radiosurgi... |
| - | Health IT company nets $5M for tool to lower readmissions | As hospitals face increased penalties for higher than average readmission rates for an expanding list of conditions, companies that can prove their technology can reduce readmissions are winning healthcare investor confidence. RightCare Sol... |
| - | Morning Read: Personal genetic map may soon be as cheap as a big screen TV | The same market forces that made computers cheaper and faster are influencing the cost of gene mapping. The team at Complete Genomics is using expertise from computer networking experience to build machines that can do genetic sequencing mo... |
| - | Benvenue Medical secures $40M Series E to beef up manufacturing, U.S. commercialization | Spine tech startup Benvenue Medical has secured a $40 million Series E, plus $24 million in debt financing, to further commercialization efforts in the States, upscale manufacturing and support growth. The Santa Clara, California-based comp... |
| - | Apnex Medical names former BSX and J&J executive as its new CEO | Apnex Medical Inc., a St. Paul-based startup developing technology to treat obstructive sleep apnea (OSA), has named Charles McKhann as its new CEO.
McKhann, who previously served as a global vice president of marketing for Boston Scientifi... |
| - | Watch out, Theranos? Edico Genome CEO backing stealth one-drop-of-blood startup | Looks like a new single-drop-of-blood startup is is in the diagnostics arena: SalveoDx, a San Diego-based spinout of Domain Associates, just raised $2 million in equity.
Pieter van Rooyen, a director at SalveoDx and CEO of San Diego-based E... |
| - | Biotech company developing therapies for macular edema raises $40 million | Alimera Sciences, a public company without any revenue, has developed a drug delivery system to be implanted at the back of the eye and has raised $40 million through a private placement with institutional investors, both new and existing. ... |
| - | Early stage biotechs face funding gap as VCs seek surer bets, stronger returns | Biotechnology companies seeking venture capital got some sobering perspective at the CED Biotech/Life Science Conference this week. Despite the talk of improving market conditions and loosening purse strings leading up to the conference in ... |
| - | Cash from innovation challenges will provide pilot testing for readmission, diabetes education software | A readmission risk assessment tool and two diabetes education programs will now be put to the ultimate reality check: patients.
The winner of the Janssen Connected Care Challenge and finalists in Sanofi’s Data Design Diabetes Innovation Cha... |
| - | Discharge decision support startup feted by Janssen raises $1.75M in series A | A health IT company that won a Janssen Innovation Challenge to devise ways to reduce unnecessary hospital readmissions has raised $1.75 million in a series A round.
RightCare Solutions‘ Discharge Decision Support System, or D2S2, uses a sco... |
| - | A look at the underbelly of Theranos, plus 5 must-read stories from MedCity News this week | This week on MedHeads, we talked Theranos – specifically, the fallout from the damning Wall Street Journal exposé that questioned the diagnostic company’s scientific underpinnings.
It’s unique for a diagnostics company to have enjoyed so mu... |
| - | Domain VC: Why we’re investing more in molecular diagnostics | When Domain Associates led Xagenic Inc.’s recent $20 million Series B, it marked the eighth diagnostics investment the firm had made with its $500 million eighth fund.
The partners say they’ve invested nearly a quarter of their current fund... |
